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Abstract 
A series of novel isocombretapyridines were designed and synthesized based on 
a lead compound isocombretastatin A-4 by replacing 3,4,5-trimethoxylphenyl with 
substituent pyridine nucleus. The MTT assay results showed that compound 20a 
possessed the most potent activities against all tested cell lines with IC50 values at 
nanomolar concentration ranges. Moreover, 20a inhibited tubulin polymerization at a 
micromolar level and also displayed potent anti-vascular activity in vitro. Further 
mechanistic studies were conducted to demonstrate that compound 20a could bind to 
the colchicine site of tubulin，and disrupted the cell microtubule networks, induced 
G2/M phase arrest, promote apoptosis and depolarized mitochondria of K562 cells in 
a dose-dependent manner. Notably, 20a exhibited more potent tumor growth 
inhibition activity with 68.7% tumor growth inhibition than that of isoCA-4 in H22 
allograft mouse model without apparent toxicity. The present results suggest that 
compound 20a may serve as a promising potent microtubule-destabilizing agent 
candidate for the development of therapeutics to treat cancer. 
Key words: isocombretapyridines, tubulin inhibitors, colchicine binding site, 
anti-vascular, antitumor.  
1. Introduction 
Microtubules, which are composed of α- and β-tubulin heterodimers and serve as 
the major component of cytoskeleton, have essential roles in several biological 
functions, such as cell proliferation, shape maintenance, intracellular trafficking, 
migration, cell division and mitosis [1-3]. Microtubules are in the state of dynamic 
equilibrium in which alternative cycling of microtubule assembly and disassembly 
take place. Accordingly, interfering with microtubule dynamic equilibrium has 
emerged as an effective strategy for the treatment of cancer [4-7]. The agents 
interfering with microtubule dynamics are classified into two main categories: 
microtubule-stabilizing agents and microtubule-destabilizing agents [8]. 
Microtubule-stabilizing agents, which can promote microtubule polymerization, 
usually bind to the taxane binding site while microtubule-destabilizing agents, which 
can promote microtubule depolymerization, usually bind to vinca alkaloid or 
colchicine binding sites [9, 10]. Compared with other sites binders, inhibitors binding 
to colchicine binding site have several advantages, such as simpler structures, 
improved aqueous solubility, reduced toxicity, additional anti-vascular activity and 
multidrug resistance (MDR) effects [11, 12]. Therefore, in recent decades, 
considerable research efforts have been devoted to developing the agents targeting 
colchicine binding site [13-15]. 
Combretastatin A-4 (CA-4, 1, Figure 1A), a representative colchicine binding site 
inhibitor derived from the African bush willow tree Combretum caffrum, displayed 
potent anticancer and anti-vascular activity [16]. CA-4 has become a structural model 
for designing new analogs due to its potent anti-vascular and anticancer profiles. 
However, CA-4 suffers from chemical instability via easy isomerization to the less 
active but thermodynamically more stable E-isomer during storage, administration 
and metabolism [17]. The discovery of new CA-4 analogs have circumvented the 
stability problem, such as isocombretastatin A-4 (isoCA-4, 2) [18] and Phenstatin (3, 
Figure 1A) [19]. IsoCA-4 with 1,1-diarylethylene scaffold possesses similar 
biological properties as CA-4 but it is more chemically and metabolically stable [18].   
Nitrogenous heterocycles, such as quinazoline, quinoline and pyridine, are common 
fragments of a vast majority of marketed drugs, which play central roles in modern 
drug design [20]. The introduced nitrogen atom may form a hydrogen bond with 
specific residues of the target receptor or receptor-bound water molecules that need to 
be satisfied [21]. Recently, some anti-tubulin agents were developed by replacing the 
3,4,5-trimethoxyphenyl ring of isoCA-4 with a quinazoline nucleus, which showed 
potent anti-proliferative activities against a range of human cancer cells, such as 
compound 4 (Figure 1B) [22]. Further docking study indicated that the N-1 atom of 
such quinazolines interacted with βCys 241 of tubulin whereas the position of the N-3 
atom of these compounds was inadequate to interact with tubulin. Accordingly, 
Alami's group reported an isoCA-4 analog 5 with a quinoline moiety that displayed a 
nano- and sub-nanomolar level of cytotoxicity against five cancer cell lines [23]. Our 
group has focused on discovering and developing novel anticancer agents targeting 
tubulin-microtubule system and some N-containing candidates were found in recent 
years, such as quinoline-chalcone derivative (6) [8] and quinoline-indole derivative (7) 
[24]. Compounds 6 and 7 were synthesized via replacing typical 
3,4,5-trimethoxyphenyl (A ring) of CA-4 with quinoline rings, which all exhibited 
potent anticancer activity both in vitro and in vivo. Very recently, the heterocyclic ring 
pyridine nucleus was firstly introduced to replace the typical 3,4,5-trimethoxyphenyl 
to afford a series of novel pyridine-chalcone derivatives by our group. Among those 
pyridine-chalcone derivatives, compound 8 effectively suppressed the tumor volume 
and reduced tumor weight by 65.8%. Further molecular modelling study revealed that 
the N-1 of pyridine moiety of 8 formed a critical hydrogen bond with residue Cys241 
[25]. Those results indicated that the substituted pyridine ring might be a good 
surrogate for the 3,4,5-trimethoxyphenyl ring of isoCA-4. 
 
Figure 1. (A) Representative anti-tubulin compounds; (B) Tubulin inhibitors bearing quinoline, 
quinazoline and pyridine moieties. 
Based on these inspiring results, in this study, compounds isoCA-4 and 8 were used 
as novel lead compounds, the systematic exploration of the structure-activity 
relationships (SARs) of these two compounds were conducted. Thus, a series of novel 
isocombretapyridines were designed by replacing the 3,4,5-trimethoxyphenyl moiety 
of compound 2 with substituted pyridine rings as ring A, and introduced ring B with 
different substituents (Figure 2). Herein, we would like to report their synthesis and 
potent antitumor activities against human cancer cell lines. In addition, the potent 
tumor growth inhibition activity in H22 allograft mouse model and the fundamental 
cytotoxic mechanisms of representative compound 20a were also elucidated. 
 
Figure 2. Design strategy of novel isocombretapyridines. 
2. Results and discussion 
2.1 Chemistry 
Target compounds 15a-d, 16a-d and 17a-f bearing 2,6-dimethoxypyridine were 
synthesized through the palladium-catalyzed cross-coupling reactions between 
N-tosylhydrazones and various aryl halides, which was developed by Alami’s group 
[26]. As outlined in Scheme 1, the starting material 2,6-dichloroisonicotinic acid was 
first reacted with N-methoxymethanamine to afford intermediate 9 which then 
underwent nucleophilic attack by methylmagnesium bromide (CH3MgBr) to give 
acetylpyridine 10. Then, acetylpyridine 10 was protected by using 2-bromoethanol in 
the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) to give acetal 11 which 
was further substituted with sodium methoxide to give intermediate 12. The 
intermediate 12 was deprotected by concentrated hydrochloric acid to afford 13 which 
was transformed into N-tosylhydrazone 14. Subsequently, N-tosylhydrazone 14 was 
coupled with various aryl bromides to afford corresponding target compounds (15a-d) 
in moderate yields, and the tert-butyldimethylsilyl (TBS) and benzenesulfonyl 
protecting groups were removed by corresponding deprotection methods. In addition, 
16a-d were methylated or hydroxymethylated to give the corresponding target 
compounds 17a-e. Compound 15d was further reduced in the presence of Pd/C under 
H2 atmosphere to give target compound 17f as a racemic mixture. 
Scheme 1. The synthetic routes for target compounds 15a-d, 16a-d and 17a-f. Reagents and 
conditions: (a) N,O-Dimethylhydroxylamine hydrochloride, HOBt, EDCI, Et3N, DCM, 30 ℃, 
overnight, 85.45%; (b) CH3MgBr, THF, N2, 0 ℃,1 h, 88.33%; (c) BrCH2CH2OH, DBU, Tol, 80 ℃, 
overnight, 72.81%; (d) MeONa, MeOH, 100 ℃, sealed tube, overnight; (e) con.HCl, 80 ℃, 1 h, 
88.26%; (f) p-toluenesulfonhydrazide, EtOH, 90 ℃, 3 h, 88.26%; (g) 1) aryl halides, 
PdCl2(CH3CN)2, Xphos, t-BuOLi, 90 ℃, 2 h, 56.51% - 72.82%; 2) TBS was removed under 
condition: TBAF, THF, 1 h or benzenesulfonyl was removed under condition: 10% NaOH, MeOH, 
reflux, 2 h, 90.51% - 92.38%; (h) CH3I, NaH, THF, r.t, 2 h, 88.6%; (i) 37% HCHO aqueous, 2M 
NaOH, EtOH, r.t, 1 h, 66.74%; (j) Pd/C, H2, r.t, 30 min, 82.75%. 
As shown in Scheme 2, isocombretapyridines with different substitutions at C-2 
and C-6 positions of pyridine were synthesized. The intermediates 18a-b were 
prepared by nucleophilic reactions of acetylpyridine 10 with methanamine or 
pyrrolidine, respectively. Intermediate 11 reacted with various secondary amines 
followed by deprotection to afford the corresponding intermediates 18c-e. Then, 
N-tosylhydrazones 19a-e and 22 were coupled with TBS-protected 
5-bromo-2-methoxyphenol, followed by deprotection to give the target compounds 
20a-e and 23. 
Scheme 2. The synthetic routes for target compounds 20a-e and 23. Reagents and conditions: (a) 
Various secondary amines, 120 - 150 ℃, sealed tube, 12 - 24 h, 85.61% - 87.67%; (b) 
methanamine or pyrrolidine, 150 ℃, sealed tube, 24 h, 65.35% - 69.37%; (c) 
p-toluenesulfonhydrazide, EtOH, 90 ℃, 3 h, 80% - 85%; (d) 1) TBS-protected 
5-bromo-2-methoxyphenol, PdCl2(CH3CN)2, Xphos, t-BuOLi, 90 ℃, 2 h, 23.57% - 69.13%; 2) 
TBAF, THF, 1 h, 95.3%. 
The synthetic routes of target compounds 27a-b and 32a-b bearing methylpyridine 
moieties were depicted in Scheme 3. The important intermediate 29 was prepared by 
the reaction of indole-5-acid (28) with lithium methide (CH3Li), the N-1 of which was 
then methylated to afford intermediate 30. The intermediates 25 and 30 reacted with 
4-methylbenzenesulfonhydrazide to give N-tosylhydrazones 26 and 31, which 
coupled with 4-chloro-2, 6-dimethylpyridine or 4-chloro-2-methylpyridine to obtain 
the corresponding target compounds 27a-b and 32a-b. 
Scheme 3. The synthetic routes for target compounds 27a-b and 32a-b. Reagents and conditions: 
(a) TBSCl, imidazole, DCM, r.t, 2 h, 95.5%; (b) p-toluenesulfonhydrazide, EtOH, 90 ℃, 3 h, 
85.7%; (c) 1) 4-chloro-2-methylpyridine or 4-chloro-2,6-dimethylpyridine, Pd(CH3CN)2Cl2, dppf, 
Cs2CO3, dioxane, Ar, 90 ℃, 3 h, 19.70% - 25.72% ; 2) TBAF，THF, r.t, 30 min, 92.5%; (d) CH3Li, 
THF, 0 ℃, 1 h, 87.97%; (e) CH3I, NaH, THF, 0 ℃, 1 h，89.71%; (f) 4-chloro-2-methylpyridine or 
4-chloro-2,6-dimethylpyridine, PdCl2(CH3CN)2, Xphos, t-BuOLi, 90 ℃, 2 h, 62.76% - 67.59%. 
2.2 In vitro cancer cell growth inhibition and the SARs. 
   The anti-proliferative activities of the firstly prepared target compounds 15a-d, 
16a-d and 17a-f with a 2,6-dimethoxypyridine moiety as the ring A were evaluated in 
human chronic myelogenous leukemia cells K562 using MTT assay, and isoCA-4 was 
used as a reference compound. As shown in Table 1, compound 15d featuring 
3-hydroxyl-4-methoxylphenyl moieties displayed the most potent anti-proliferative 
activity with an IC50 value of 0.044 μM, which was about seven-fold more potent than 
the olefin-reduced racemic mixture of 17f (IC50 = 0.308 μM). However, compounds 
16a-d, of which olefin were substituted at different positions of indole ring, displayed 
lower activity (IC50 > 1 μM). Further, the anti-proliferative activities of substitutions 
at N-1 position of indole ring on activity were evaluated, compounds 17a-e containing 
methyl and hydroxymethyl group displayed similar activity compare to 16a-d except 
compound 17d with olefin substituted at C-5 position of indole rings, which exhibited 
moderate anti-proliferative activity (IC50 = 0.181 μM).  
  Furthermore, to investigate the importance of various substituents on the C-2 and 
C-6 of pyridine derivative 15d, compounds 20a-e, 23, 27a-b and 32a-b were 
synthesized by replacements of the methoxyl substituent. Compounds 20a, 20c, 27a-b 
and 32a-b all exhibited more potent anti-proliferative activity than 15d. Steric 
hindrance of the groups at the C-2 and C-6 position of the pyridine moiety seemed to 
play an important role on the activity, as compounds with small steric groups 
displayed more potent anti-proliferative activity than those with large steric groups 
(20a vs 20e). However, compound 23, with no substitution at C-2 and C-6 position of 
the pyridine nucleus, displayed a decreasing cytotoxicity against K562 cells when 
compared to 15d, though the methoxy group has a larger steric hindrance.  
Table 1. Anti-proliferative activities of all isocombretapyridines against K562 cell line a 
Compd. 
IC50 values (μM) 
b 
Compd. 
IC50 values (μM) 
b 
K562 K562 
15a > 1 17f 0.308 ± 0.031  
15b > 1 20a 0.01 ± 0.001  
15c > 1 20b > 1 
15d 0.044 ± 0.003  20c 0.016 ± 0.022 
16a > 1 20d > 1 
16b > 1 20e > 1 
16c > 1 23 0.151 ± 0.012  
16d > 1 27a 0.024 ± 0.002 
17a > 1 27b 0.012 ± 0.001 
17b > 1 32a 0.028 ± 0.002  
17c > 1 32b 0.021 ± 0.001 
17d 0.181 ± 0.014 isoCA-4 0.006 ± 0.001 
17e > 1   
a K562, human chronic myelogenous leukemia cells; 
b IC50 values are indicated as the mean ± SD (standard deviation) of at least three independent 
experiments. 
According to the results from K562 cell cytotoxicity assay, ten representative 
compounds were selected to test their anti-proliferative activities against three 
additional human cancer cell lines including human hepatocellular carcinoma 
(HepG2), human ileocecal cancer cells (HCT-8) and human breast cancer cells 
(MDA-MB-231), and one human normal lung fibroblast cell line (HFL-1). IsoCA-4 
was utilized as the reference compound. The cytotoxic data in Table 2 indicated that 
the IC50 values of the representative compounds against three cancer cell lines were in 
nanomolar ranges and they also exhibited good selectivity against normal cell line 
HFL-1 cells. Moreover, the SARs were similar to their performances in K562 cell, 
which was the most sensitive cell line among four tested cell lines. Among them, 
compound 20a bearing 2-chloro-6-methyaminopyridine moiety exhibited the most 
excellent cytotoxicity activity with IC50 values ranging from 10 to 21 nM. The SARs 
of these novel isocombretapyridines were summarized in Figure 3. 
Table 2. Cytotoxic activities of the selected compounds against three human cancer cell lines and 
one normal cell line a. 
Compd. 
IC50 values (μM) 
b 
HepG2 HCT-8 MDA-MB-231 HFL-1 
15d 0.077 ± 0.011 0.086 ± 0.012 0.084 ± 0.014 0.792 ± 0.054 
17d 0.3 ± 0.022 0.288 ± 0.019 0.308 ± 0.032 0.879 ± 0.062 
17f 0.756 ± 0.042 0.794 ± 0.045 0.711 ± 0.038 1.104 ± 0.103 
20a 0.019 ± 0.002 0.021 ± 0.003 0.02 ± 0.001 0.118 ± 0.007 
20c 0.027 ± 0.003 0.029 ± 0.003 0.029 ± 0.002 0.114 ± 0.006 
23 0.261 ± 0.022 0.222 ± 0.019 0.208 ± 0.018 0.696 ± 0.048 
27a 0.031 ± 0.003 0.032 ± 0.004 0.031 ± 0.003 0.189 ± 0.018 
27b 0.027 ± 0.002 0.031 ± 0.003 0.029 ± 0.003 0.086 ± 0.012 
32a 0.033 ± 0.001 0.032 ± 0.002 0.035 ± 0.002 0.201 ± 0.025 
32b 0.03 ± 0.001 0.031 ± 0.002 0.034 ± 0.003 0.176 ± 0.018 
isoCA-4 0.01 ± 0.001 0.01 ± 0.001 0.012 ± 0.002 0.086 ± 0.010 
a Cells were treated with different concentrations of the compounds for 72 h. Cell viability was 
measured by the MTT assay as described in the Experimental Section. 
b IC50 values are indicated as the mean ± SD (standard error) of at least three independent 
experiments. 
 
Figure 3. Summarized SARs of novel isocombretapyridines bearing different ring B. 
2.3 Analysis of tubulin polymerization in vitro 
To investigate whether the anti-proliferative activity of target compounds was 
caused by an interaction with tubulin system, the representative compound 20a was 
selected to evaluate the inhibitory effects on tubulin polymerization in vitro with 
isoCA-4 as the reference compound. The typical microtubule-destabilizing agent 
colchicine and microtubule-stabilizing agent taxol were employed as the positive 
control and negative control, respectively. As shown in Figure 4, taxol increased the 
absorbance obviously indicating that it enhanced tubulin polymerization, while 20a, 
isoCA-4 and colchicine decreased the absorbance, indicating that the tubulin 
polymerization was inhibited. Moreover, compound 20a (IC50 = 3.15 μM) exhibited 
only slightly less potent tubulin polymerization inhibitory activity than isoCA-4 (IC50 
= 2.37 μM) (Table 3). These results suggested that the mechanism of compound 20a 
was consistent with previously reported microtubule-destabilizing agents, certifying 
that compound 20a is a novel microtubule-destabilizing agent.  
 
Figure 4. The compound 20a inhibited microtubule assembly in vitro. Purified tubulin protein at 2 
mg/mL in a reaction buffer incubated at 37 °C in the presence of 1% DMSO, test compounds (20a 
and isoCA-4 at 5 or 10 μM) or colchicine (10 μM). Polymerizations were followed by an increase 
in fluorescence emission at 350 nm over a 60 min period at 37 °C. The experiments were 
performed three times. 
Compound 20a was also evaluated for potential inhibition of the binding of 
[3H]colchicine to tubulin. As shown in Table 3, 20a inhibited the binding of 
[3H]colchicine with the inhibition rates of 66.45% and 79.30% at 1 and 5 μM, 
respectively, somewhat less potent than isoCA-4 (74.04 % and 84.56 %). Therefore, 
due to its excellent activities both in the in vitro anti-proliferative assay and tubulin 
polymerization inhibition assay, 20a was selected for further mechanism studies.  
Table 3. Inhibition of tubulin polymerization a and colchicine binding to tubulin b 
Compd. Inhibition of tubulin polymerization 
Inhibition of colchicine binding 
(%) inhibition ± SD 
IC50 (μM) 1 μM 5 μM 
20a 3.15 ± 0.26 66.45 ± 2.73 79.30 ± 1.66 
isoCA-4 2.37 ± 0.21 74.04 ± 2.52 84.56 ± 3.09 
a The tubulin assembly assay measured the extent of assembly of 2 mg/mL tubulin after 60 min at 
37 °C. Data are presented as mean from three independent experiments. 
b Tubulin, 1 μM; [3H]-colchicine, 5 μM; and inhibitors, 1 or 5 μM. 
2.4 Molecular docking. 
The binding mode of compound 20a at the colchicine binding site of tubulin was 
performed using the Ligand Docking program in the Schrödinger software. As shown 
in Figure 5A, the superimposition of the best poses of docked compound 20a with 
CA-4 in the tubulin clearly demonstrated that compounds 20a and CA-4 adopt a 
similar binding mode in the colchicine binding pocket, with the 
2-chloro-6-methyaminopyridine moiety deeply buried into the hydrophobic pocket 
shaped by residues βVal238, βCys241, βLeu242, βLeu248, βAla250, βLeu255, 
βAla316, βIle318 and βIle378. The docking pose for compound 20a showed a 
docking score of -8.850 kcal/mol, which was similar to the score obtained for the 
crystallized CA-4 (-8.595 kcal/mol). And one hydrogen bond was formed between 
3’-OH of 20a and CA-4 and the main-chain amide of αThr179. The N atom of 
pyridine ring formed a pivotal hydrogen bond with residue βCys241, which was 
resembled with that of the 4-methoxy group of isoCA-4 (Figure 5B). Meanwhile, the 
methylamino group of pyridine ring formed an additional hydrogen bond interaction 
with residue βVal238. In conclusion, the docking studies further suggested that 20a 
bound to the colchicine binding site on tubulin.  
 
Figure 5. Proposed binding model of 20a (green) with tubulin (PDB code: 5LYJ), (A) 
Overlapping with CA-4 (cyan); (B) Overlapping with isoCA-4 (violet). The hydrogen bonds were 
shown in yellow dashed lines.  
2.5 Effects on cell cycle distribution and apoptosis assay  
It has been reported that the G2/M phase cell-cycle arrest is a hallmark of 
tubulin-polymerizing inhibitors [27]. Thus, the cellular mechanisms of the 
representative compound 20a were further investigated using propidiumiodide (PI) 
staining by flow cytometry analysis in K562 cells, and isoCA-4 was used as the 
reference compound. K562 cells were treated with 20a at 5 nM, 10 nM and 20 nM 
(0.5-fold, 1-fold and 2-fold IC50) in parallel with isoCA-4 at 3 nM, 6 nM and 12 nM. 
As shown in Figure 6C and D, when treated with isoCA-4 at indicated concentration, 
the population of cells in G2/M increased from 7.83% to 18.44% at high 
concentration compared with vehicle control. Simultaneously, compared to the 
vehicle control (7.70%), 9.40%, 11.54% and 15.28% of cells were arrested at G2/M 
phase in the presence of compound 20a at 5, 10 and 20 nM, respectively, which were 
similar to isoCA-4 (Figure 6A and B). Those results revealed that K562 cells treated 




Figure 6. Compound 20a induced K562 cells cycle arrest at G2/M phase. A) K562 cells were 
treated with varying concentrations of 20a (0, 5, 10, and 20 nM) for 48 h, harvested and stained 
with PI to measure cell cycle profile by flow cytometry. The percentages of cells at different 
phases of cell cycle were analyzed by ModFit 4.1; B) Histograms display the percentage of cell 
cycle distribution after treatment with 20a; C) Cell cycle distribution of K562 cells cell lines after 
treatment with isoCA-4 at different concentration (0, 3, 6, and 12 nM); D) Histograms display the 
percentage of cell cycle distribution after treatment with isoCA-4. 
Mitotic arrest of tumor cells by tubulin-targeting inhibitors is generally associated 
with cellular apoptosis [28]. To investigate the ability of compound 20a to induce 
apoptosis, an Annexin V-FITC/PI (AV/PI) dual staining assay was performed on K562 
cells by flow cytometry [29]. The results were illustrated in Figure 7. Compared to the 
percentage of apoptosis cells in control group (3.25%), the total percentage of the 
early (Annexin-V+/PI−) and late (Annexin-V+/PI+) apoptosis cells were 10.46%, 
48.55% and 62.26% after being treated with 20a at 5, 10, and 20 nM for 48 h, 
respectively. It determined that compound 20a significantly induces cell apoptosis in 
K562 cells in a concentration-dependent manner.  
 
Figure 7. Compound 20a induced K562 cell apoptosis. A) K562 cells were incubated with 
varying concentrations of 20a (0, 5, 10, and 20 nM) for 48 h, and then harvested and stained with 
Annexin V/PI, followed by flow cytometric analysis. The percentages of cells in each stage of cell 
apoptosis were quantified by flow cytometry: (upper left quadrant) necrosis cells; (upper right 
quadrant) late-apoptotic cells; (bottom left quadrant) live cells; and (bottom right quadrant) early 
apoptotic cells. (B) Histograms display the percentage of cell distribution after treatment with 20a. 
2.6 Mitochondrial membrane potential analysis. 
The decrease of mitochondrial membrane potential (MMP) has been considered as 
an early event in apoptotic cells, and many antimitotic derivatives induce apoptosis 
through the mitochondrial pathway [30]. To confirm whether compound 20a could 
decrease the MMP of cancer cells, mitochondrial membrane potential assay by JC-1 
staining of mitochondria in K562 was performed [31]. As shown in Figure 8, after 
exposure of K562 cells to various concentrations of compound 20a (0, 5, 10 and 20 
nM), the percentage of cells with collapsed MMP increased from 1.57% to 38.34%, 
indicated that compound 20a induces MMP collapse and mitochondrial dysfunction, 
which eventually triggered apoptotic cell death.  
Figure 8. Assessment of mitochondrial membrane potential after treatment of K562 cells with 20a. 
A) The K562 cells were treated with 20a at 5, 10, and 20 nM or DMSO (1%) for 48 h, then 
incubated with the fluorescent probe JC-1 for 30 min. The number of cells with collapsed 
mitochondrial membrane potentials was analyzed by flow cytometry. (B) Histograms display the 
percentage of green fluorescence. 
2.7 Anti-microtubule effects in K562 cells. 
To evaluate the effects of compound 20a on microtubule networks, 
immunofluorescent assay was performed on K562 cells. As shown in Figure 9, K562 
cells in control group exhibited normal filamentous arrays. However, after treatment 
with increasing dosages of compound 20a (5, 10 and 20 nM) for 24 h, the microtubule 
networks in cytoplasm were decreased and disrupted, which indicated that compound 
20a could affect the cellular microtubule dynamics in a dose-dependent manner. 
 
Figure 9. Immunofluorescence assay on microtubule network of K562 treated with 20a. K562 
cells were treated with vehicle control 0.1% DMSO, 20a (5, 10 and 20 nM). Then, the cells were 
fixed and stained with anti-α-tubulin-FITC antibody (green), Alexa Fluor 488 dye and 
counterstained with DAPI (blue). The detection of the fixed and stained cells was performed with 
an LSM 570 laser confocal microscope (Carl Zeiss, Germany). 
2.8 Evaluation of anti-vascular activity in vitro.   
Angiogenesis, the development of the new blood vessels, plays a vital role in 
human cancer progression, development, and metastasis [32]. The agents binding to 
colchicine site can target tumor vasculature and prevent the formation of new blood 
vessels or disrupt existing microvessels [33]. Microtubules-targeting agents have also 
been reported to interfere with cell migration and motility at low concentrations. We 
evaluated the capacity of compound 20a to inhibit cell migration using a wound 
healing assay. As shown in Figure 10A and 10B, the control HUVECs that was not 
treated showed a wound closure of 76.3%. However, after exposed to compound 20a 
at 5, 10, and 20 nM for 24 h, cells migrated into 67.6%, 55.3% and 49.2% of the 
wound area, respectively, suggesting that compound 20a significantly decreases 
wound closure in a concentration-dependent manner.  
The HUVEC tube formation assay, a dynamic in vitro assay representing the key 
steps in angiogenesis [34, 35], was performed to assess the effect of compound 20a on 
inhibiting HUVECs capillary-like tubules formation. As shown in Figure 10C, after 
treatment with 5, 10 and 20 nM of compound 20a, HUVEC tube formation was 
inhibited in a concentration-dependent manner. These results indicated that compound 




Figure 10. Effect of 20a on the HUVECs migration and tube formation. A) Scratches were created 
with sterile 200 μL pipette and images were captured using phase contrast microscopy at 0 h and 
B ) 
24 h after treatments with 20a at different concentrations (5, 10 and 20 nM) or 1% DMSO. B) 
Histograms display the length of the scratches at 0 h and 24 h after treatments with 0, 5, 10 and 20 
nM of 20a, ***P < 0.001 vs control group. C) Images depicting the formation of HUVEC 
capillary-like tubular network by treatments with 0, 5, 10 and 20 nM of 20a for 6 h.  
2.9 Growth inhibition of mouse H22 allograft model in vivo.  
To investigate the in vivo antitumor potency of compound 20a, the liver tumor 
allograft mouse model was established by subcutaneously injecting H22 cells at the 
logarithmic growth phase into the right flank of mice. IsoCA-4 and taxol was 
employed as the reference and positive control. In the initial MTT assay, the 20a, 
isoCA-4 and taxol displayed the potent anti-proliferative activity against H22 cells 
with the IC50 value of 0.017 μM, 0.008 μM and 0.084 μM, respectively. The doses for 
compounds 20a and isoCA-4 were selected 15 and 30 mg/kg as group. All results 
were represented in Figure 11, compound 20a displayed obvious and dose-dependent 
antitumor effect. The decrease in tumor weight reached 68.7% at doses of 30 mg/kg 
per day (i.v.) of 20a at 21 days after initiation of treatment as compared to vehicle, 
which is more potent than isoCA-4 (inhibition rate: 66.9% at a dose of 30 mg/kg) and 
taxol ( 64.3%, at a dose of 6 mg/kg), respectively (Figure 11D). Importanly, in 
comparison with the control and vehicle groups, 20a did not cause an obvious loss of 
body weight even at the dose of 30 mg/kg, which demonstrated that 20a displayed no 
significant toxicity in these mice (Figure 11C). To further evaluate the potential 
organ-related toxicities of 20a, the H&E staining was conducted. As shown in Figure 
12, the results of H&E staining of the heart, liver, spleen, lung and kidneys showed 
that treatment with 20a (30 mg/kg) did not cause obvious toxicity in mice. All results 
indicated that compound 20a was efficacious and safe in inhibiting the growth of 
tumor in vivo and deserved further investigations for cancer therapy. 
 
Figure 11. 20a inhibited liver tumor growth in vivo. After administered with vehicle, taxol (6 
mg/kg per 2 days), 20a (15 mg/kg per day), 20a (30 mg/kg per day), isoCA-4 (15 mg/kg per day), 
and isoCA-4 (30 mg/kg per day) for three weeks, the mice were sacrificed, and the tumors were 
weighted. (a) The images of tumors from mice at 21 days after initiation of treatment. (b) Tumor 
volume changes of mice during treatment. (c) Body weight changes of mice during treatment. (d) 
The weight of the excised tumors of each group. ***P < 0.001 vs control group. 
 
Figure 12. H&E staining of heart, liver, spleen, lung, and kidney of 20a-treated mice. The organs 
(the heart, liver, spleen, lung and kidney) fixed by paraformaldehyde were processed for paraffin 
embedding and then stained with hematoxylin and eosin. The images shown are representatives 
from each group. 
3. Conclusion  
  In conclusion, twenty-four novel isocombretapyridines were designed, synthesized 
and evaluated as tubulin polymerization inhibitors. Ten of the novel 
isocombretapyridines exhibited anti-proliferative activities against four cancer cell 
lines with IC50 values at nanomolar concentration ranges. Among them, compound 
20a displayed the most potent anti-proliferative activity with IC50 values ranging from 
0.01 to 0.021 μM. Moreover, 20a showed good tubulin polymerization inhibitory 
activity (IC50 = 3.15 μM), which was correlated with inhibition of [
3H]colchicine 
binding to tubulin. Further cellular mechanistic studies indicated that 20a disrupted 
microtubule networks, arrested cell cycle at G2/M phase, induced apoptosis and 
depolarized mitochondria of K562 cells in a dose-dependent manner. Moreover, 20a 
displayed potent anti-vascular activity in both HUVECs wound healing and tube 
formation assays. Importantly, in a H22 liver cancer allograft mouse model, 20a could 
effectively suppressed the tumor volume and reduced tumor weight by 68.7% at the 
dose of 30 mg/kg per day (i.v.) without apparent toxicity. Collectively, these results 
highlighted that 20a may be a promising potent antitumor and anti-vascular candidate 
for the treatment of cancers, which deserves further investigation. 
4. Experimental section 
4.1 Chemistry  
4.1.1 General 
All commercially available starting materials and solvents were reagent grade and 
used without further purification unless otherwise noted. 1H NMR and 13C NMR 
spectra were recorded on Bruker-300 or Bruker-400 spectrometers using CDCl3 or 
DMSO-d6 as solvent (TMS as internal standard). Data are reported as follows: 
chemical shift (δ) in ppm, multiplicity (s: singlet, d: doublet, t: triplet, q: quartet, brs:  
broad singlet, m: multiple), coupling constant J (Hz), and integration. High 
Resolution Mass measurement was performed on Agilent QTOF 6520 mass 
spectrometer with electron spray ionization (ESI) as the ion source. Flash column 
chromatography was carried out using commercially available silica gel (200 - 300 
mesh) under pressure. The purity of the representative compounds is ≥ 95% as 
analyzed by the HPLC (Shimadzu LC-20AT) on an Aglient ZORBAX Eclipse Plus 
C18 (4.6 × 150 mm, 5 μm) using a mixture of solvent 0.1% trifluoroacetic 
acid/acetonitrile at the flow rate of 1.0 mL/min and peak detection at 254 nm under 
UV 
4.1.2 The synthesis of intermediate 9. 
  2,6-Dichloroisonicotinic acid (10 g, 54.6 mmol), N,O-dimethylhydroxylamine 
hydrochloride (7.99 g, 81.89 mmol), HOBt (8.85 g, 65,52 mmol) and EDCI (12.56 g, 
65.52 mmol) were dissolved in DCM and Et3N (11.38 mL, 81.89 mmol) was added. 
After being stirred at room temperature overnight, the reaction mixture was filtered 
and the solvent was evaporated in vacuo. The crude product was purified by column 
chromatography with petroleum / ethyl acetate (4:1) to give intermediate 9 as a white 
solid (9.97 g, 85.45%); 1H NMR (300 MHz, CDCl3) δ 7.50 (s, 2H), 3.58 (s, 3H), 3.37 
(s, 3H). 
4.1.3 The synthesis of intermediate 10. 
  The intermediate 9 (9.97 g, 42.41 mmol) were dissolved in anhydrous THF and 
methylmagnesium bromide in THF (3 M, 14.14 mL, 42.41 mmol) was added slowly 
under N2 atmosphere at 0 ℃. After stirring for 1 h, the reaction was quenched by 
NH4Cl aqueous, and extracted with CH2Cl2 (3 × 150 mL). The combined organic 
layers were then washed with brine, dried over anhydrous Na2SO4, and concentrated 
under a vacuum to obtain 10 (7.12 g, 88.33%) as yellow liquid, the crude product was 
used without purification; 1H NMR (300 MHz, CDCl3) δ 7.69 (s, 2H), 2.64 (s, 3H). 
4.1.4 The synthesis of intermediate 11. 
  The intermediate 10 (7.12 g, 37.47 mmol) and 2-bromoethanol (13.27 mL, 187.35 
mmol) were dissolved in toluene and DBU (16.81 mL, 112.41 mmol) was added 
dropwise, then the mixture was stirred at 90 ℃. After stirring overnight, toluene was 
removed under a vacuum to obtain crude product which was purified by column 
chromatography with petroleum / ethyl acetate (30:1) to give intermediate 11 as a 
white solid (6.385 g, 72.81%); 1H NMR (300 MHz, CDCl3) δ 7.73 (s, 2H), 4.03 (t, J = 
6.8 Hz, 2H), 3.67 (t, J = 6.9 Hz, 2H), 1.76 (s, 3H). 
4.1.5 The synthesis of intermediate 12. 
  To the solutions of 11 (4 g, 17.09 mmol) in 20 mL MeOH at sealed tube, sodium 
methoxide (9.23 g, 170.88 mmol) was added. After stirring at 100 ℃ overnight, the 
mixtures were cooled to room temperature, and the solvent was removed in vacuo. 
After being extracted with EA (3 × 120 mL), the combined organic layers were 
washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo to 
provide 3.48 g crude intermediate 12 as a yellow solid; 1H NMR (300 MHz, CDCl3) δ 
6.03 (s, 2H), 3.93 (t, J = 6.7Hz, 2H), 3.83 (s, 6H), 3.64 (t, J = 6.5 Hz, 2H), 1.68 (s, 
3H). 
4.1.6 The synthesis of intermediate 13. 
  The 3.48 g crude intermediate 12 was added in 20 mL concentrated hydrochloric 
acid. After stirring for 1 h at 80 ℃, 2 M NaOH was added to adjust the pH to 8. The 
solution was extracted with EA (3 × 100 mL), then the collected organic layers were 
washed with saturated brine, dried over anhydrous Na2SO4, and concentrated in vacuo 
to afford the crude product. The crude product was purified by column 
chromatography with petroleum / ethyl acetate (40:1) to give intermediate 13 (2.48 g, 
88.26%) as a light yellow solid; 1H NMR (300 MHz, CDCl3) δ 6.74 (s, 2H), 3.95 (s, 
6H), 2.55 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 212.5, 164.1, 148.7, 99.7, 53.9, 27.0. 
4.1.7 The synthesis of intermediate 14. 
  The intermediate 13 (2.48 g, 13.69 mmol) was dissolved in EtOH and 
4-methylbenzenesulfonohydrazide (3.06 g, 16.42 mmol) was added. After stirring for 
3 h at 80 ℃, the precipitates were collected by filtration, washed with cold EtOH and 
dried to afford intermediate 14 (3.95 g, 82.26%) as a light yellow solid. 
4.1.8 The synthesis of target compounds 15a-d and 16a-d. 
  To a solution of the key intermediate 14 (75 mg, 0.16mmol) in 2 mL dioxane under 
N2 atmosphere, the various aryl bromides (0.18 mmol), Xphos (8 mg, 0.016 mmol), 
Pd(CH3CN)2Cl2 (4 mg, 0.016mmol) and t-BuOLi (29 mg, 0.36 mmol) were added. 
After stirring for 3 h at 90 ℃, the precipitates were removed by filtration. And the 
filtrates were concentrated under a vacuum to afford the crude products, which were 
purified by column chromatography with petroleum/ethyl acetate to give compounds 
15a-c in moderate yields. To a solution of TBS-protected 15d (68 mg, 0.17 mmol) in 
5 mL THF, TBAF were added. After stirring for 30 min, the solvent was removed to 
obtain crude product, which was purified by column chromatography with 
petroleum/ethyl acetate (6: 1) to give compounds 15d (45 mg, 92.50%). To a solution 
of benzenesulfonyl-protected 16a-d in 5 mL MeOH, 10% NaOH solution was added. 
After stirring for 2 h at refluxing temperature, MeOH was removed in vacuo. The 
mixture was extracted with EA (3 × 50 mL), and the combined organic layers were 
then washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo to 
provide the crude product, which was purified by column chromatography with 
petroleum/ethyl acetate to give 16a-d in moderate yields. 
4.1.8.1 4-(1-(Benzo[d][1,3]dioxol-5-yl)vinyl)-2,6-dimethoxypyridine (15a). 
  Yield 66.8%, white solid; 1H NMR (300 MHz, CDCl3) δ 6.81 (d, J = 1.7 Hz, 1H), 
6.81 – 6.77 (m, 2H), 6.29 (s, 2H), 5.99 (s, 2H), 5.46 (d, J = 1.0 Hz, 2H), 3.94 (s, 6H); 
13C NMR (101 MHz, CDCl3) δ 165.9, 163.3, 154.6, 147.8, 147.5, 134.2, 122.0, 115.1, 
108.5, 108.1, 101.2, 100.8, 53.6; HR-MS (ESI) m/z: calcd for C16H16NO4 [M+H]
+
 
286.1074, found 286.1077. 
4.1.8.2 4-(1-(3,4-Dimethoxyphenyl)vinyl)-2,6-dimethoxypyridine (15b). 
Yield 60%, yellow solid; 1H NMR (300 MHz, CDCl3) δ 6.87 – 6.84 (m, 1H), 6.85 – 
6.78 (m, 2H), 6.28 (d, J = 1.4 Hz, 2H), 5.46 (s, 2H), 3.92 (s, 6H), 3.90 (s, 3H), 3.85 (s, 
3H); 13C NMR (75 MHz, CDCl3) δ 163.3, 154.7, 149.1, 148.7, 147.9, 132.9, 120.9, 
114.9, 111.3, 110.9, 100.7, 55.9, 53.5; HR-MS (ESI) m/z: calcd for C17H20NO4 
[M+H]+ 302.1387, found 302.1390. 
4.1.8.3 2, 6-Dimethoxy-4-(1-(3,4,5-trimethoxyphenyl)vinyl)pyridine (15c). 
  Yield 65%, yellow oil; 1H NMR (300 MHz, CDCl3) δ 6.51 (s, 2H), 6.29 (s, 2H), 
5.53 (s, 1H), 5.48 (s, 1H), 3.93 (s, 6H), 3.87 (s, 3H), 3.82 (s, 6H); 13C NMR (101 
MHz, CDCl3) δ 163.3, 154.3, 152.95, 148.3, 138.0, 135.8, 115.9, 105.5, 100.7, 60.9, 
56.2, 53.6; HR-MS (ESI) m/z: calcd for C18H22NO5 [M+H]
+
 332.1492, found 
332.1497; Purity: 99.66% (by HPLC). 
4.1.8.4 5-(1-(2,6-Dimethoxypyridin-4-yl)vinyl)-2-methoxyphenol (15d). 
Yield 58.4%, yellow solid; 1H NMR (300 MHz, CDCl3) δ 6.92 (s, 1H), 6.79 (d, J = 
1.3 Hz, 2H), 6.27 (s, 2H), 5.60 (s, 1H), 5.46 (s, 1H), 5.42 (s, 1H), 3.91 (s, 6H), 3.90 (s, 
3H); 13C NMR (75 MHz, CDCl3) δ 163.2, 154.7, 147.7, 146.5, 145.3, 133.4, 120.1, 
115.0, 114.3, 110.2, 100.8, 56.0, 53.6; HR-MS (ESI) m/z: calcd for C16H18NO4 
[M+H]+ 288.1230, found 288.1230; Purity: 99.79% (by HPLC). 
4.1.8.5 3-(1-(2,6-Dimethoxypyridin-4-yl)vinyl)-1H-indole (16a). 
  Yield 67.7%, yellow oil; 1H NMR (300 MHz, CDCl3) δ 8.21 (s, 1H), 7.61 (d, J = 
8.0 Hz, 1H), 7.40 (d, J = 8.1 Hz, 1H), 7.25 – 7.19 (m, 1H), 7.17 – 7.09 (m, 2H), 6.42 
(s, 2H), 5.65 (d, J = 1.4 Hz, 1H), 5.52 (d, J = 1.4 Hz, 1H), 3.92 (s, 6H); 13C NMR 
(101 MHz, CDCl3) δ 163.3, 162.3, 155.7, 141.5, 136.5, 124.4, 122.5, 120.5, 120.3, 
113.9, 111.4, 102.0, 100.6, 53.7; HR-MS (ESI) m/z: calcd for C16H18NO4 [M+H]
+
 
281.1285, found 281.1286. 
4.1.8.6 3-(1-(2,6-Dimethoxypyridin-4-yl)vinyl)-6-methoxy-1H-indole (16b). 
  Yield 72.8%, yellow oil; 1H NMR (300 MHz, CDCl3) δ 8.09 (s, 1H), 7.47 (d, J = 
8.8 Hz, 1H), 7.01 (d, J = 2.5 Hz, 1H), 6.88 (d, J = 2.4 Hz, 1H), 6.80 (dd, J = 8.8, 2.3 
Hz, 1H), 6.41 (s, 2H), 5.62 (d, J = 1.4 Hz, 1H), 5.47 (d, J = 1.4 Hz, 1H), 3.92 (s, 6H), 
3.85 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 163.3, 162.3, 123.3, 121.1, 120.4, 116.6, 
115.9, 113.4, 110.2, 109.1, 100.6, 98.9, 94.8, 55.7, 53.6; HR-MS (ESI) m/z: calcd for 
C18H19N2O3 [M+H]
+
 311.1390, found 311.1391. 
4.1.8.7 4-(1-(2,6-Dimethoxypyridin-4-yl)vinyl)-1H-indole (16c). 
 Yield 56.51%, green oil; 1H NMR (300 MHz, CDCl3) δ 8.20 (s, 1H), 7.38 (d, J = 8.1 
Hz, 1H), 7.24 – 7.10 (m, 2H), 7.04 (d, J = 7.2 Hz, 1H), 6.31 (s, 2H), 6.27 (s, 1H), 5.81 
(d, 1H), 5.62 (d, 1H), 3.89 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 163.4, 154.9, 147.5, 
136.0, 132.9, 126.7, 124.1, 121.8, 120.6, 117.5, 110.9, 102.5, 100.2, 53.6; HR-MS 
(ESI) m/z: calcd for C17H17N2O2 [M+H]
+
 281.1285, found 281.1286. 
4.1.8.8 5-(1-(2,6-Dimethoxypyridin-4-yl)vinyl)-1H-indole (16d). 
Yield 67.72%, colorless oil; 1H NMR (300 MHz, CDCl3) δ 8.14 (s, 1H), 7.52 (d, J 
= 1.6 Hz, 1H), 7.28 (d, J = 8.5 Hz, 1H), 7.16 (t, J = 2.8 Hz, 1H), 7.10 (dd, J = 8.4, 1.7 
Hz, 1H), 6.47 (d, J = 2.7 Hz, 1H), 6.27 (s, 2H), 5.46 (d, J = 1.2 Hz, 1H), 5.43 (s, 1H), 
3.85 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 163.3, 155.7, 149.2, 135.6, 132.1, 127.8, 
124.8, 122.6, 120.6, 114.7, 110.7, 103.0, 100.9, 53.6; HR-MS (ESI) m/z: calcd for 
C17H17N2O2 [M+H]
+
 281.1285, found 281.1289. 
4.1.9 The synthesis of target compounds 17a-d. 
To a solution of intermediates 16a-d (1 eq.) in DMF, NaH (1.5 eq.) was added. 
After stirring for 10 min at 0 ℃, CH3I (1.5 eq.) was added dropwise, then the reaction 
mixture was warmed to room temperature. After stirring for 2 h at room temperature, 
the reaction was quenched with water, extracted with EA, washed with water (3 × 50 
mL), and the organic layers were then washed with brine, dried over anhydrous 
Na2SO4, and concentrated in vacuo. The crude product was purified by column 
chromatography with petroleum/ethyl acetate to give 17a-d.  
4.1.9.1 3-(1-(2,6-Dimethoxypyridin-4-yl)vinyl)-1-methyl-1H-indole (17a). 
  Yield 76.19%, colorless oil; 1H NMR (300 MHz, CDCl3) δ 7.66 – 7.61 (m, 1H), 
7.36 – 7.31 (m, 1H), 7.25 (d, J = 7.1 Hz, 1H), 7.17 – 7.10 (m, 1H), 6.98 (s, 1H), 6.48 
– 6.35 (m, 2H), 5.63 (d, J = 1.4 Hz, 1H), 5.46 (d, J = 1.5 Hz, 1H), 3.92 (s, 6H), 3.77 (s, 
3H); 13C NMR (75 MHz, CDCl3) δ 163.1, 162.0, 134.0, 129.1, 126.5, 125.6, 122.0, 
120.6, 120.1, 109.5, 109.1, 102.0, 100.8, 53.4, 45.5; HR-MS (ESI) m/z: calcd for 
C18H19N2O2 [M+H]
+
 295.1441, found 295.1439. 
4.1.9.2 3-(1-(2,6-Dimethoxypyridin-4-yl)vinyl)-6-methoxy-1-methyl-1H-indole (17b). 
Yield 16.19%, white solid; 1H NMR (300 MHz, CDCl3) δ 7.49 (d, J = 8.6 Hz, 1H), 
6.85 (s, 1H), 6.82 – 6.74 (m, 2H), 6.41 (s, 2H), 5.61 – 5.56 (m, 1H), 5.40 (d, J = 1.5 
Hz, 1H), 3.92 (s, 6H), 3.88 (s, 3H), 3.70 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 163.2, 
156.5, 156.0, 141.6, 138.2, 128.2, 121.3, 120.8, 112.7, 109.7, 100.7, 98.8, 93.0, 55.7, 
53.6, 32.9; HR-MS (ESI) m/z: calcd for C19H21N2O3 [M+H]
+
 325.1547, found 
325.1544. 
4.1.9.3 4-(1-(2,6-Dimethoxypyridin-4-yl)vinyl)-1-methyl-1H-indole (17c). 
Yield 62.57%, yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.32 (d, J = 8.2 Hz, 1H), 
7.22 (t, J = 7.7 Hz, 1H), 7.03 (d, J = 7.1 Hz, 1H), 6.99 (d, J = 3.2 Hz, 1H), 6.31 (s, 
2H), 6.20 (d, J = 3.1 Hz, 1H), 5.80 (s, 1H), 5.65 – 5.59 (m, 1 H), 3.89 (s, 6H), 3.80 (s, 
3H); 13C NMR (75 MHz, CDCl3) δ 163.3, 154.9, 147.5, 136.9, 133.0, 128.8, 127.3, 
121.4, 120.1, 117.4, 109.1, 100.9, 100.2, 53.6, 33.0; HR-MS (ESI) m/z: calcd for 
C18H19N2O2 [M+H]
+
 3295.1441, found 295.1444; Purity: 98.19% (by HPLC). 
4.1.9.4 5-(1-(2,6-Dimethoxypyridin-4-yl)vinyl)-1-methyl-1H-indole (17d). 
Yield 74.21%, yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.57 (s, 1H), 7.29 (s, 1H), 
7.19 (dd, J = 8.5, 1.7 Hz, 1H), 7.07 (d, J = 3.0 Hz, 1H), 6.46 (d, J = 3.1 Hz, 1H), 6.33 
(s, 2H), 5.53 (s, 1H), 5.49 (s, 1H), 3.92 (s, 6H), 3.81 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 163.3, 155.7, 149.2, 136.5, 131.5, 129.5, 128.3, 122.1, 120.8, 114.7, 108.9, 




4.1.20 The synthesis of target compounds 17e.  
  The 16d (80 mg, 0.29 mmol) was dissolved in EtOH, and 37% HCHO aqueous (2 
mL) and 2M NaOH aqueous (2 mL) were added. After stirring for 1 h at room 
temperature, the solvent was removed under a vacuum. The residue was extracted 
with EA (3 × 50 mL), and the combined organic layers were then washed with brine, 
dried over anhydrous Na2SO4, and concentrated in vacuo to provide the crude product, 
which was purified by column chromatography with petroleum/ethyl acetate (10: 1 to 
3: 1) to give 17e (60 mg, 66.74%) as a white solid; 1H NMR (300 MHz, CDCl3) δ 
7.57 (s, 1H), 7.44 (d, J = 8.5 Hz, 1H), 7.24 (d, J = 1.8 Hz, 1H), 7.20 (d, J = 3.2 Hz, 
1H), 6.52 (d, J = 3.2 Hz, 1H), 6.32 (s, 2H), 5.64 (d, J = 5.0 Hz, 2H), 5.52 (d, J = 7.0 
Hz, 2H), 3.91 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 163.3, 155.5, 148.9, 135.5, 132.6, 
129.2, 128.0, 122.7, 121.0, 115.0, 109.3, 103.3, 100.8, 69.9, 53.7; HR-MS (ESI) m/z: 
calcd for C18H19N2O3 [M+H]
+
 311.1390, found 311.1395. 
4.1.21 The synthesis of target compound 17f.  
Compound 15d (60 mg, 0.21 mmol) was dissolved in 5 mL EtOH, Pd/C was added. 
After stirring for 30 min, the solution was collected by filtration, concentrated under a 
vacuum to obtain crude product, which was purified by column chromatography with 
petroleum/ethyl acetate (15: 1) to give compound 17f (50 mg, 82.75%) as a white 
solid; 1H NMR (300 MHz, CDCl3) δ 6.78 (s, 1H), 6.75 (s, 1H), 6.69 (d, J = 8.3 Hz, 
1H), 6.21 – 6.13 (m, 2H), 5.60 – 5.53 (m, 1H), 3.87 (s, 6H), 3.86 (s, 3H), 1.58 – 1.51 
(m, 3H); 13C NMR (75 MHz, CDCl3) δ 163.3, 161.1, 145.5, 145.2, 138.1, 118.9, 113.9, 
110.6, 100.2, 56.0, 53.5, 43.8, 21.1; HR-MS (ESI) m/z: calcd for C16H20NO4 [M+H]
+
 
290.1387, found 290.1386. 
4.1.22 The synthesis of intermediates 18a-e. 
  To a solution of intermediate 10 or 11 (300 mg) in 2 mL EtOH in sealed tube was 
added various amines (10 eq.). The mixture was stirred at 150 ℃ for 12 - 24 h. Then, 
the mixture was concentrated in vacuo to afford the crude products, which were 
purified by column chromatography with petroleum/ethyl acetate to give 18a-e as 
yellow solids. 
4.1.23 The synthesis of target compounds 20a-e and 23. 
The target compounds 20a-e and 23 were prepared using the same procedures of 
15d in moderate yields. 
4.1.23.1 5-(1-(2-Chloro-6-(methylamino)pyridin-4-yl)vinyl)-2-methoxyphenol (20a). 
Yield 69.13%, white solid; 1H NMR (300 MHz, CDCl3) δ 6.92 (d, J = 1.9 Hz, 1H), 
6.84 – 6.75 (m, 2H), 6.55 (d, J = 1.1 Hz, 1H), 6.19 (d, J = 1.1 Hz, 1H), 5.73 (s, 1H), 
5.48 (d, J = 1.0 Hz, 1H), 5.42 (d, J = 1.0 Hz, 1H), 4.77 (d, J = 5.4 Hz, 1H), 3.91 (s, 
3H), 2.89 (d, J = 5.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 159.7, 153.5, 149.5, 
147.2, 146.7, 145.4, 133.0, 120.1, 115.4, 114.3, 111.7, 110.3, 103.3, 56.0, 29.2; 
HR-MS (ESI) m/z: calcd for C15H16ClN2O2 [M+H]
+
 291.0895, found 291.0898; Purity:  
100.00% (by HPLC). 
4.1.23.2 5-(1-(2,6-Di(pyrrolidin-1-yl)pyridin-4-yl)vinyl)-2-methoxyphenol (20b). 
Yield 67.28%, white solid; 1H NMR (300 MHz, CDCl3) δ 7.25 (d, J = 1.8 Hz, 1H), 
7.03 (d, J = 2.2 Hz, 1H), 6.90 – 6.85 (m, 1H), 6.78 – 6.73 (m, 1H), 5.58 (s, 2H), 5.40 
(d, J = 1.6 Hz, 1H), 5.36 (d, J = 1.8 Hz, 1H), 3.89 (d, J = 1.7 Hz, 3H), 3.41 (d, J = 6.5 
Hz, 8H), 1.92 (q, J = 4.2 Hz, 8H); 13C NMR (75 MHz, CDCl3) δ 156.9, 151.6, 149.7, 
146.3, 145.1, 134.3, 120.1, 114.2, 112.9, 110.0, 93.7, 56.0, 46.5, 25.5; HR-MS (ESI) 
m/z: calcd for C22H28N3O2 [M+H]
+
 366.2176, found 366.2182. 
4.1.23.3 5-(1-(2-Chloro-6-(dimethylamino)pyridin-4-yl)vinyl)-2-methoxyphenol (20c). 
Yield 57.97%, offwhite solid; 1H NMR (400 MHz, CDCl3) δ 6.93 (d, J = 1.9 Hz, 
1H), 6.79 (d, J = 3.1 Hz, 1H), 6.49 (d, J = 1.1 Hz, 1H), 6.29 (d, J = 1.1 Hz, 1H), 5.60 
(s, 1H), 5.47 (d, J = 1.1 Hz, 1H), 5.40 (d, J = 1.1 Hz, 1H), 3.91 (s, 3H), 3.06 (s, 6H); 
13C NMR (75 MHz, CDCl3) δ 159.2, 153.1, 149.4, 147.6, 146.6, 145.3, 133.2, 120.0, 
115.1, 114.2, 110.5, 110.3, 103.4, 56.0, 38.1; HR-MS (ESI) m/z: calcd for 
C16H18ClN2O2 [M+H]
+
 305.1051, found 305.1051; Purity: 98.54% (by HPLC). 
4.1.23.4 5-(1-(2,6-Dimorpholinopyridin-4-yl)vinyl)-2-methoxyphenol (20d). 
Yield 61.05%, white solid; 1H NMR (400 MHz, CDCl3) δ 6.98 (d, J = 2.0 Hz, 1H), 
6.84 (d, J = 2.0 Hz, 1H), 6.81 (d, J = 8.4 Hz, 1H), 6.00 (s, 2H), 5.64 (s, 1H), 5.46 (d, J 
= 1.3 Hz, 1H), 5.37 (d, J = 1.3 Hz, 1H), 3.93 (s, 3H), 3.84 – 3.80 (m, 8H), 3.50 – 3.45 
(m, 8H); 13C NMR (75 MHz, CDCl3) δ 158.5, 153.0, 149.2, 146.5, 145.3, 133.8, 
119.9, 114.2, 113.8, 110.2, 96.7, 66.9, 56.0, 45.7; HR-MS (ESI) m/z: calcd for 
C22H28N3O4 [M+H]
+
 398.2074, found 398.2076. 
4.1.23.5 5-(1-(2-Chloro-6-(piperazin-1-yl)pyridin-4-yl)vinyl)-2-methoxyphenol (20e). 
Yield 23.57%, white solid; 1H NMR (300 MHz, Methanol-d4) δ 6.90 (d, J = 8.1 Hz, 
1H), 6.75 (d, J = 2.1 Hz, 2H), 6.58 (d, J = 7.0 Hz, 2H), 5.49 (s, 1H), 5.44 (s, 1H), 3.87 
(s, 3H), 3.58 (t, J = 5.1 Hz, 4H), 3.03 (t, J = 5.1 Hz, 4H); 13C NMR (101 MHz, CDCl3) 
δ 158.5, 154.0, 149.7, 147.2, 146.8, 145.5, 132.9, 120.0, 115.7, 114.2, 113.3, 110.4, 




4.1.23.6 2-Methoxy-5-(1-(pyridin-4-yl)vinyl)phenol (23). 
Yield 39.7%, white solid; 1H NMR (400 MHz, CDCl3) δ 8.51 (d, J = 6.2 Hz, 2H), 
7.26 (t, J = 1.3 Hz, 1H), 7.25 (d, J = 1.7 Hz, 1H), 6.85 (d, J = 8.9 Hz, 1H), 6.83 – 6.80 
(m, 2H), 5.55 (d, J = 0.9 Hz, 1H), 5.47 (d, J = 0.9 Hz, 1H), 3.91 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 149.8, 149.1, 147.4, 147.2, 146.0, 132.7, 123.3, 119.6, 115.8, 114.7, 
110.8, 56.0; HR-MS (ESI) m/z: calcd for C14H14NO2 [M+H]
+ 228.1019, found 
228.1022. 
4.1.24 The synthesis of target compounds 27a-b. 
  To a solution of intermediate 26 (150 mg, 0.33 mmol) in 2 mL dioxane at sealed 
tube under N2 atmosphere, 4-chloro-2-methylpyridine (42.65 mg, 0.33 mmol) or 
4-chloro-2,6-dimethylpyridine (47.34 mg, 0.33 mmol), dppf (18.54 mg, 0.033 mmol), 
Pd(CH3CN)2Cl2 (8.67 mg, 0.033 mmol) and Cs2CO3 (272.33 mg, 0.84 mmol) were 
added. The post-treatment of 27a-b was similar to that of 15d. The target compounds 
27a-b were obtain in low yields. 
4.1.24.1 2-Methoxy-5-(1-(2-methylpyridin-4-yl)vinyl)phenol (27a). 
Yield 19.7%, white solid; 1H NMR (400 MHz, CDCl3) δ 8.39 (d, J = 5.2 Hz, 1H), 
7.10 (d, J = 1.6 Hz, 1H), 7.06 (dd, J = 5.3, 1.7 Hz, 1H), 6.84 (d, J = 1.9 Hz, 2H), 6.79 
(dd, J = 1.7, 0.8 Hz, 1H), 5.53 (d, J = 1.0 Hz, 1H), 5.43 (d, J = 0.9 Hz, 1H), 3.92 (s, 
3H), 2.53 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 158.1, 150.0, 148.5, 147.4, 147.2, 
145.9, 132.9, 122.8, 120.5, 119.6, 115.5, 114.5, 110.7, 56.0, 24.1; HR-MS (ESI) m/z: 
calcd for C15H16NO2 [M+H]
+ 242.1172, found 242.1172. 
4.1.24.2 5-(1-(2,6-Dimethylpyridin-4-yl)vinyl)-2-methoxyphenol (27b). 
Yield 25.72%, white solid; 1H NMR (400 MHz, CDCl3) δ 8.44 (s, 1H), 6.90 (s, 2H), 
6.88 (d, J = 1.9 Hz, 1H), 6.87 (s, 1H), 6.67 (d, J = 1.9 Hz, 1H), 5.51 (d, J = 1.0 Hz, 
1H), 5.38 (d, J = 1.1 Hz, 1H), 3.93 (s, 3H), 2.49 (s, 6H); 13C NMR (75 MHz, CDCl3) 
δ 157.0, 150.8, 147.8, 147.5, 146.4, 132.6, 120.3, 118.9, 115.1, 114.2, 111.1, 55.9, 
23.5; HR-MS (ESI) m/z: calcd for C16H18NO2 [M+H]
+ 256.1332, found 256.1332. 
4.1.25 The synthesis of intermediate 29. 
   The 1H-indole-5-carboxylic acid (1.5 g, 9.31 mmol) was dissolved in THF under 
Ar atmosphere and CH3Li (1.5 M, 20.48 mL, 30.71 mmol) was added dropwise at 0 ℃. 
After stirring for 12 h, the reaction was quenched with water, extracted with EA (3 × 
150 mL), and the combined organic layers were then washed with brine, dried over 
anhydrous Na2SO4, and concentrated in vacuo to provide the crude product, which 
was purified by column chromatography with petroleum/ethyl acetate (4: 1) to give 29 
(1.30 g, 87.97%) as a yellow oil. The spectra data were consistent with the literature 
[29]. 
4.1.26 The synthesis of target compounds 32a-b. 
The target compounds 32a-b were prepared using the same procedures of 15a-c in 
moderate yields. 
4.1.26.1 1-Methyl-5-(1-(2-methylpyridin-4-yl)vinyl)-1H-indole (32a). 
Yield 62.76%, yellow solid; 1H NMR (400 MHz, CDCl3) δ 8.44 (t, J = 4.1 Hz, 1H), 
7.54 (d, J = 1.8 Hz, 1H), 7.29 (dd, J = 8.4, 2.7 Hz, 1H), 7.17 (dd, J = 8.4, 1.8 Hz, 1H), 
7.14 (s, 1H), 7.10 (dd, J = 5.2, 1.8 Hz, 1H), 7.07 (t, J = 2.9 Hz, 1H), 6.47 (d, J = 3.0 
Hz, 1H), 5.56 (s, 1H), 5.51 (s, 1H), 3.81 (s, 3H), 2.54 (s, 3H); 13C NMR (101 MHz, 
CDCl3) δ 158.3, 150.4, 149.2, 149.1, 136.6, 131.5, 129.6, 128.4, 122.6, 122.1, 120.8, 
120.3, 115.1, 109.0, 101.4, 33.0, 24.5; HR-MS (ESI) m/z: calcd for C17H17N2 [M+H]
+ 
249.1386, found 256.1388; Purity: 97.21% (by HPLC). 
4.1.26.2 5-(1-(2,6-Dimethylpyridin-4-yl)vinyl)-1-methyl-1H-indole (32b). 
Yield 67.59%, yellow solid; 1H NMR (300 MHz, CDCl3) δ 7.55 (s, 1H), 7.28 (s, 
1H), 7.18 (s, 1H), 7.08 (s, 1H), 6.96 (s, 2H), 6.48 (s, 1H), 5.55 (s, 1H), 5.52 – 5.46 (m, 
1H), 3.82 (s, 3H), 2.52 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 157.6, 150.7, 149.4, 
136.5, 131.7, 129.6, 128.4, 122.1, 120.8, 119.8, 114.9, 109.0, 101.4, 33.0, 24.5; 
HR-MS (ESI) m/z: calcd for C18H19N2 [M+H]
+ 263.1543, found 263.1544; Purity: 
99.35% (by HPLC). 
4.2 Pharmacology 
4.2.1 Anti-proliferative studies                                                                                     
All cell lines were purchased from Nanjing KeyGen Biotech Co. Ltd. (Nanjing, 
China). The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide 
(MTT) assay was performed to evaluate the anti-proliferative activity of the 
compounds. The cell lines were cultured in 96-well cell culture plate containing 
growth medium at 37 ℃ in a humidified 5% CO2 incubator for 24 h. Then, the cells 
were treated with 100 μL tested compounds at 9 different final concentration. After 72 
h of incubation, 10 μL MTT was added to 96-well cell culture plate and incubated for 
1-2 h before the absorbance was recorded at 450 nm with a spectrophotometric plate 
reader. The dose−response curves were plotted with Graph Prism software, and the 
IC50 values were calculated using the Graph Prism software from polynomial curves. 
All experiments were measured at least three times. 
4.2.2 Analysis of tubulin polymerization in vitro and competitive inhibition assays 
An in vitro assay for monitoring the time-dependent polymerization of tubulin to 
microtubules was performed. An amount of 2 mg/mL tubulin (Cytoskeleton) was 
suspended with PEM buffer containing 80 mM piperazine-N,N’-bis(2-ethanesulfonic 
acid) sequisodium salt PIPES (pH 6.9), 0.5 mM EGTA, 2 mM MgCl2, and 15% 
glycerol. Then the mixture was preincubated with tested compounds or vehicle 
DMSO on ice for 5 min. PEG containing GTP was added to the final concentration of 
3 mg/mL before detecting the tubulin polymerization reaction. The OD values at 340 
nm were determined through Berthold LB941 microplate multi-function microplate 
reader. 
The radiolabeled [3H] colchicine competitive scintillation approximation (SPA) was 
used to evaluate the competitive binding activity of the inhibitors. The 0.08 μM [3H] 
colchicine, the tested compounds with different concentration and 0.5 μg tubulin were 
added to the 100 μL buffer containing 80 mM PIPES (pH 6.9), 0.5 mM EGTA, 2 mM 
MgCl2, and 15% glycerol. After incubation for 2 h, streptavidin-labeled SPA beads 
(80 μg) were added to mixture and the sample was counted using a TopCountTM 
Microplate Scintillation Counter. 
4.2.3 Cell cycle analysis 
Exponentially growing K562 cancer cells were incubated with 20a at 
concentrations of 5, 10, and 20 nM and isoCA-4 at 3, 6, and 12 nM in 6-well culture 
cell plates for 72 h, with 1% DMSO as vehicle control group. After collection using 
0.25% trypsin, the cells were washed twice with PBS buffer. The collected cells were 
fixed by adding 70% ethanol at 4 ℃ for 12 h. After being washed with PBS, 100 μL 
RNase was added, then 400 μL PI was used to stain for 30 min. The cell cycle 
distribution was examined by a FACScan flow cytometer (BectoneDickinson, USA), 
and the data were analyzed using the Modfit program (BectoneDickinson, USA). 
4.2.4 Apoptosis assay. 
Annexin V-FITC/PI dual staining assay was performed to determine the cells 
apoptosis. K562 cells were incubated with 5, 10, and 20 nM compound 20a in 6-well 
cell culture plates for 72 h. The cells were washed twice in PBS, then 500 μL binding 
buffer suspended cells were added. The cells were stained with 5 μL Annexin V-FITC 
and PI. Then the cells were incubated at room temperature for 20 min without light 
exposure. Apoptosis was analyzed using a FACS Calibur flow cytometer (Bectone 
Dickinson, San Jose, CA, USA). 
4.2.5 Immunofluorescence staining. 
 After being cultured in 6-well cell culture plates, K562 cells were treated with 5, 
10, and 20 nM compound 20a or vehicle control 1% DMSO. After being fixed with 
4% paraformaldehyde, the cells were penetrated with PBS for three times and blocked 
with 50-100 μL goat serum albumin at room temperature for 20 min. Then they were 
incubated with rabbits anti-α-tubulin antibody (UK, Abcam, ab6046) for 2 h at 37 °C 
and then incubated with goat anti-rabbit IgG-TRITC (Nanjing KeyGen Biotech Co. 
Ltd., China) at 37 °C for 1 h. After being washed three times by PBS, the cells were 
counterstain using 4,6-diamidino-2-phenylindole (DAPI). Cells were finally 
visualized under a fluorescence microscope (OLYMPUS, Japan). 
4.2.6 Mitochondrial membrane potential analysis. 
A lipophilic cationic dye, 5, 5′, 6, 6′-tetrachloro-1, 1′, 3, 3 
-tetraethylbenzimidazolcarbocyanine (JC-1) was used to monitor the level of MMP in 
the cells by flow cytometry. K562 cells were seeded in 6-well cell culture plates and 
cultivated for 24 h, then incubated with 20a at 5, 10 and 20 nM for 24 h. After being 
washed with PBS buffer, the cells were harvested by centrifugation and resuspended 
in 500 μL JC-1 incubation buffer at 37 °C for 15-20 min. After briefly washing, the 
proportion of red fluorescence intensity was immediately detected and analyzed by 
flow cytometry (Bectone-Dickinson, San Jose, CA, USA). 
4.2.7 Tube Formation Assay. 
The HUVECs cells were seeded in 6-well plates and cultivated for 24 h, then 
incubated with 5, 10, and 20 nM 20a. The EC Matrigel matrix was thawed at 4 °C 
overnight, and HUVECs suspended in F12K were seeded in 96-well culture plates at a 
cell density of 50 000 cells/well after polymerization of the Matrigel at 37 °C for 30 
min. They were then treated with 20 μL different concentrations of 20a or vehicle for 
6 h at 37 °C. Then, the morphological changes of the cells and tubes formed were 
observed and photographed under an inverted microscope (OLYMPUS, Japan). 
4.2.8 Wound Healing Assays. 
K562 cells were seeded in 6-well plates and cultivated for 24 h. Scratches were 
made in confluent monolayers using 200 μL pipette tips. Then, wounds were washed 
twice with PBS to remove nonadherent cell debris. The media containing different 
concentrations (0, 5, 10, and 20 nM) of 20a were added to the Petri dishes. Cells 
which migrated across the wound area were photographed using phase contrast 
microscopy at 0 and 24 h. The migration distance of cells migrated to the wound area 
was measured manually. 
4.2.9 In vivo antitumor activity assay. 
  Five-week-old male Institute of Cancer Research (ICR) mice were purchased from 
Shanghai SLAC Laboratory Animals Co. Ltd. A total of 1 × 106 H22 cells were 
subcutaneously inoculated into the right flank of ICR mice according to protocols of 
tumor transplant research, to initiate tumor growth. After incubation for one day, mice 
were weighted and divided into eight groups at random with eight animals in each 
group. The groups treated with 20a were administered 15, 30 mg/kg in a vehicle of 
10% DMF/2% Tween 80/88% saline, respectively. The positive control group was 
treated with taxol (6 mg/kg) every 2 days by intravenous injection, while isoCA-4 was 
administered 15 and 30 mg/kg in a vehicle of 10% DMF/2% Tween 80/88% saline. 
The negative control group received a vehicle of 10% DMF/2% Tween 80/88% saline 
through intravenous injection. Treatments of 20a and isoCA-4 were done at a 
frequency of intravenous injection one dose per day for a total 21 consecutive days 
while the positive group was treated with taxol one dose per two days. The mice were 
executed after the treatments and the tumors were excised and weighed. The 
inhibition rate was calculated as follows: Tumor inhibitory ratio (%) = (1-average 
tumor weight of treated group/average tumor weight of control group) × 100%. 
4.2.10 H&E staining. 
The Mouse organs (heart, liver, spleen, lung, kidney) were isolated, then which 
were fixed in 4% paraformaldehyde and embedded in paraffin using tissue embedding 
machine. The tissues were sectioned in the vertical plane into 5 μm-thick. Then, 
sections were prepared orderly by dewaxing, stainingm and dehydration. After 
staining in Harris hematoxylin solution, sections were stained in eosin-phloxine 
solution for 1 min and then dehydrated and mounted with neutral resin. The tissue 
morphology was observed under a microscope. 
4.2.11 Molecular docking study. 
  Based on our previous study, the X-ray structure of α, β-tubulin in complex with 
CA-4 was downloaded from the Protein Data Bank (PDB code: 5LYJ) [36]. The 
protein was prepared by the Protein Preparation Wizard module in Schrodinger. The 
compound 20a, CA-4 and isoCA-4 were prepared by the Ligprep module in 
Schrodinger Suite, and were minimized by OPLS-2005 force field. The docking 
procedure was performed by employing Glide extra precision (Glide-XP) in Ligand 
Docking program in Schrodinger, and the structural image was obtained using 
PyMOL Molecular Graphics System version 2.7. 
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